Renal effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence  by Stasch, Johannes-Peter et al.
Renal effects of soluble guanylate cyclase stimulators
and activators: A review of the preclinical evidence
Johannes-Peter Stasch1,2, Jens Schlossmann3 and
Berthold Hocher4
Available online at www.sciencedirect.com
ScienceDirectDirect stimulation of soluble guanylate cyclase (sGC) is
emerging as a potential new approach for the treatment of renal
disorders. sGC catalyzes the formation of cyclic guanosine
monophosphate (cGMP), deficiency of which is implicated in
the pathogenesis of chronic kidney disease (CKD). Therefore,
new classes of drugs — sGC stimulators and activators — are
being investigated in preclinical models under conditions
where nitric oxide is deficient. In preclinical models with
different etiologies of CKD, the sGC stimulators BAY 41-2272,
BAY 41-8543, BAY 60-4552, riociguat and vericiguat and the
sGC activators cinaciguat, ataciguat, BI 703704 and
GSK2181236A have shown consistently renoprotective
effects. Clinical trials are required to confirm these findings in
humans, and to ascertain whether these agents could provide a
future alternative to guideline-recommended treatments.
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Introduction
Chronic kidney disease (CKD), defined as a reduced
estimated glomerular filtration rate (<60 ml/min/
1.73 m2), increased urinary albumin excretion (>30 mg/
g of creatinine), or both, is a substantial cause of morbidity
and mortality worldwide, and a growing public health
concern [1,2]. The estimated global prevalence of CKD is
8–16% in the general population, rising to over 50% in
high-risk subgroups [1,3]; however, few drugs for kidney
disease have been successfully developed over the past
15 years [4]. While many therapeutic interventions havewww.sciencedirect.com initially appeared effective in animal models, translation
of these results into humans in the clinical setting has
remained challenging [5]. There is a particularly high
unmet medical need for new therapies in cases where
guideline-recommended CKD treatments are unsuccess-
ful. These patients are likely to have persistent high
blood pressure and increased albumin excretion, which
puts them at increased risk of rapid progression to end-
stage renal disease (ESRD) [6–8].
Direct stimulation of soluble guanylate cyclase (sGC) is a
novel therapeutic approach under investigation for vari-
ous cardiovascular disorders associated with endothelial
dysfunction. It has also been shown to have beneficial
effects on renal tissue remodeling and organ function [9].
This review will focus on preclinical data on two classes of
compounds that directly modulate sGC, sGC stimulators,
and sGC activators. These compounds increase cyclic
guanosine monophosphate (cGMP) formation under nor-
mal conditions and conditions where nitric oxide (NO)
formation and bioavailability are impaired or NO toler-
ance has developed [10]. Given their non-overlapping
mechanism of action compared with current therapies,
activators and stimulators of sGC may offer an alternative
option for patients who are unresponsive to available
modalities and who therefore are at high risk of rapidly
progressing to more serious disease.
Pathogenesis of CKD
Excessive accumulation of extracellular matrix occurs in
virtually every type of CKD, leading to renal fibrosis [5].
Three key pathways have been identified in promoting
tissue matrix expansion: firstly, elevated synthesis of
extracellular matrix components; secondly, increased in-
hibition of matrix degradation; and finally, upregulated
local expression of integrins [11]. This pathogenic process
is progressive and ultimately leads to ESRD [5]. There
are believed to be several pathways of progression toward
ESRD at the cellular and molecular level; injury to the
tubulointerstitium, the renal parenchyma comprising the
tubules and bounded by the vasculature and nephrons,
may be one of these pathways [12].
NO and cGMP deficiency are implicated in the patho-
genesis of multiple organ systems, including the cardio-
vascular system and importantly, the renal system [10].
NO deficiency has been documented in numerous
experimental and human renal diseases, including hyper-
tension and diabetic nephropathy, glomerulosclerosis,Current Opinion in Pharmacology 2015, 21:95–104
96 Cardiovascular and renalobstructive nephropathy, and chronic interstitial nephri-
tis, as well as renal diseases due to cyclosporine A and
radiocontrast media [13–21].
Pharmacological blockade of NO has been utilized to
study the effects of NO inhibition in animal models of
renal disease. In a rat model of obstructive nephropathy,
increased fibrosis and apoptosis, and reduced blood flow
and filtration rates were observed with the use of the NO
synthase inhibitor L-NAME as compared with control
animals [13]. In another study in rats, increased arterial
pressure and reduced renal blood flow were observed as a
result of treatment with L-NAME. The hemodynamic
effects induced by NO inhibition were normalized by
sGC activation, demonstrating that the function of NO is
mediated by the cGMP pathway [22]. Together, this
research has demonstrated that NO and cGMP deficiency
contribute to the progression of CKD through both he-
modynamic and direct pro-fibrotic effects. It also reveals a
protective role of NO on renal function, interstitial fibro-
sis, and renal tubular apoptosis [13]. More than 80% of
patients with CKD are hypertensive [23], and in most, if
not all cases, the dominating pathohistological feature of
their underlying kidney disorder is accumulation of ex-
tracellular matrix proteins [5].
Due to the established link between NO deficiency and
vascular pathophysiology, targeting of the NO signaling
pathway has become a therapeutic strategy; for example,
organic nitrates have been used to treat cardiovascular
disease for more than 150 years [24]. However, resistance
to NO, non-specific, and cytotoxic effects and other
limitations associated with such treatments have led to
an interest in targeting the sGC pathway directly, result-
ing in the discovery and development of sGC stimulators
and activators [24].
Soluble guanylate cyclase
The enzyme sGC is a heterodimeric complex composed
of two subunits (a and b), and is responsible, across
various species and systems, for catalyzing cGMP forma-
tion from guanosine triphosphate. The prosthetic heme
moiety at the b-subunit of sGC is essential for NO
binding and subsequent enzyme activation [10]. NO is
produced in response to physiological stimuli such as
shear stress, and induces relaxation in the cardiovascular
system through its modulation of sGC and cGMP levels,
and consequent regulation of vascular tone and blood
pressure. Under conditions where NO formation and
bioavailability are impaired or NO tolerance has been
established, two classes of compounds have been devel-
oped that can directly modulate sGC and increase cGMP
formation: sGC stimulators and sGC activators [10].
Stimulators and activators of sGC target the enzyme in
two different redox states: the NO-sensitive reduced
(ferrous) enzyme and NO-insensitive oxidized (ferric)Current Opinion in Pharmacology 2015, 21:95–104 enzyme, and finally heme-free enzyme, respectively
(Figure 1). Stimulators of sGC stimulate the reduced
form of sGC directly and synergize with NO by stabilizing
the nitrosyl–heme complex of reduced sGC [24]. Con-
versely, sGC activators increase the activity of the en-
zyme only when the heme iron is oxidized which
subsequently lead to the heme-free enzyme. They bind
to the unoccupied heme-binding complex, and produce
only an additive effect with NO. In certain cases, sGC
activators also protect sGC from oxidation-induced pro-
teasomal degradation [24].
sGC stimulators
Effect of sGC stimulators in experimental kidney and
cardiovascular disease
In 1994, scientists at Bayer started a screening for sub-
stances that could induce an increase in NO synthesis and
thereby stimulate sGC in porcine endothelial cells. This
screening led to the unexpected discovery of NO-inde-
pendent sGC stimulators. At the same time it was
reported that a benzyl indazole compound named YC-1
inhibited platelet aggregation by stimulation of cGMP
synthesis. This compound was subsequently character-
ized as a direct NO-independent, but heme-dependent,
sGC stimulator [10,25]. Kidney fibrosis induced by uni-
lateral ureter ligation was inhibited by YC-1 via activation
of cGMP-dependent protein kinase I [26]. However,
along with its relatively weak sGC stimulating potency,
it revealed a poor pharmacokinetic profile and a lack of
specificity, as it was found to inhibit phosphodiesterases
and to modulate many cGMP-independent effects [27].
Therefore, further optimization of potency, pharmacoki-
netic properties, and specificity was required to realize
the full therapeutic potential of this novel class of drugs
[25]. Since YC-1, the sGC stimulators BAY 41-2272, BAY
41-8543, BAY 60-4552, riociguat, and vericiguat have
been developed, and their effects have been investigated
in experimental models of kidney and cardiovascular
disease [9,28–41,42,43,44]. A summary of some of the
results of these investigations is given below and in
Table 1 and Figure 2.
BAY 41-2272 and BAY 41-8543
Administration of BAY 41-2272 to rats with an acute form
of glomerulonephritis attenuated renal dysfunction, as
determined by significant reductions in proteinuria and
systolic blood pressure (Figure 2a) as compared with
untreated and control animals [36]. This effect was ac-
companied by decreased transforming growth factor beta
(TGFb) production, matrix deposition, and macrophage
infiltration, which was found to occur independently of
changes in blood pressure [36]. In another study, using
the same model, BAY 41-2272 elevated cGMP levels in
mesangial cells, thereby reducing their proliferation and
matrix production compared with placebo-treated ani-
mals. Again, treated rats had significantly lower protein-
uria levels than controls and the effects were found towww.sciencedirect.com
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Soluble guanylate cyclase stimulators and activators target two different redox states of the enzyme (reproduced from [24,25]). Soluble guanylate
cyclase (sGC) stimulators and activators target two different states of sGC: the nitric oxide (NO)-sensitive reduced, native sGC, and the NO-
insensitive oxidized, heme-free sGC. Stimulators of sGC stabilize the nitrosyl–heme complex of the reduced sGC (shown left) and exhibit a strong
synergism with NO. Activators of sGC bind to the unoccupied heme-binding complex (shown right) or displace the prosthetic heme of sGC and
protect sGC from proteasomal degradation. cGMP, cyclic guanosine monophosphate; eNOS, endothelial nitric oxide synthase.have a direct pressure-independent component [30].
Furthermore, BAY 41-2272 was shown to significantly
limit the course of chronic glomerulonephritis in a rat
model [41]. Improvements in kidney function, as assessed
by lower plasma creatinine and urea levels, were ob-
served. A further study found that BAY 41-2272 protected
the kidney from progressive sclerosis and matrix deposi-
tion by limiting TGFb expression [42].
Both BAY 41-2272 and BAY 41-8543, when administered
orally, produced dose-dependent vasodilation and
markedly improved survival, compared with untreated
controls, in rat models of hypertension, without causing
tolerance [39,40]. In aged spontaneously hypertensive
rats, BAY 41-2272 rapidly reversed existing pathological
cardiac changes, for example by decreasing fibrosis levels
to those of age-matched normotensive rats [31].
Studies in L-NAME-induced low-NO rat models of hy-
pertension demonstrated that BAY 41-8543 had a renal
protective effect (decreased plasma levels of urea andwww.sciencedirect.com creatinine compared with untreated controls) [40], while
BAY 41-2272 attenuated cardiac fibrosis (Figure 2b) and
hypertrophy [44]. In other studies, and at a dose below
that affecting blood pressure, BAY 41-2272 nevertheless
attenuated cardiac fibrosis in rodent models of hyperten-
sion induced by infusion of angiotensin II [33] or supra-
renal aortic constriction [34]. These findings suggest that
sGC stimulation may protect against organ injury inde-
pendently of its effects on vascular tone.
Increased cGMP production and subsequently enhanced
renal recovery after unilateral ureteral obstruction relief
was observed with sGC stimulation by BAY 41-8543 in a
rat model, compared with obstruction relief alone [43].
This suggests that BAY 41-8543 may serve as a novel
treatment approach to restore or preserve renal structure
and function in cases of obstructive kidney disease [45].
BAY 60-4552
Limited published data are currently available for
the other sGC stimulator, BAY 60-4552. However, inCurrent Opinion in Pharmacology 2015, 21:95–104
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Table 1
Summary of studies investigating sGC stimulators in experimental models of kidney and cardiovascular disease [9,28–41,42,43,44]
Citation Compound Treatment groups Key findings
Peters et al.,
2004 [36]
BAY 41-2272 PBS control
OX-7 only
OX-7 + BAY 41-2272
Administration of BAY 41-2272 to rats with an acute form of
glomerulonephritis induced by OX-7 antibody injection attenuated
renal dysfunction, as determined by the presence of proteinuria.
This effect was accompanied by decreased TGFb production,
fibronectin, PAI-1, matrix deposition, and macrophage infiltration.
In general, the fibrotic response in this model was not altered by
blood pressure lowering alone
Hohenstein et al.,
2005 [30]
BAY 41-2272 OX-7 + vehicle
OX-7 + BAY 41-2272
BAY 41-2272 elevated cGMP levels in mesangial cells, thereby
reducing their proliferation and matrix production in experimental
glomerulonephritis
Wang et al.,
2005 [41]
BAY 41-2272 Nonnephrectomy + PBS
Uninephrectomy + PBS
Uninephrectomy + anti-thy1
Uninephrectomy + anti-
thy1 + BAY 41-2272
Uninephrectomy + anti-
thy1 + hydralazine
Bay 41-2272 limited the progressive course of anti-thy1-induced
chronic glomerulosclerosis toward tubulointerstitial fibrosis and
impaired renal function, at least in part in a blood pressure-
independent manner, suggesting that sGC stimulation counteracts
fibrosis and progression in chronic renal disease
Wang et al.,
2006 [42]
BAY 41-2272 Nonnephrectomy + PBS
Uninephrectomy + PBS
Uninephrectomy + anti-thy1
Uninephrectomy + anti-
thy1 + BAY 41-2272
Uninephrectomy + anti-
thy1 + pentoxifylline
In a chronic model of glomerulonephritis, BAY 41-2272 protected
the kidney from progressive sclerosis and matrix deposition by
limiting TGFb expression; BAY 41-2272 administration resulted in
marked reductions of glomerular and tubulointerstitial histological
matrix accumulation, expression of TGFb1 and fibronectin,
macrophage infiltration, and cell proliferation, as well as improving
renal function. The protective effect achieved by elevating cGMP
via direct sGC stimulation with BAY 41-2272 was superior to that
produced by preventing degradation of cGMP using the non-
specific PDE inhibitor pentoxifylline
Zanfolin et al.,
2006 [44]
BAY 41-2272 Untreated control
L-NAME only
L-NAME + BAY 41-2272
BAY 41-2272
In a low-NO rat model of hypertension BAY 41-2272 attenuated
cardiac fibrosis and hypertrophy
Masuyama et al.,
2006 [33]
BAY 41-2272 Placebo control
BAY 41-2272 low
(2 mg/kg/day)
BAY 41-2272 high
(10 mg/kg/day)
Ang II + placebo
Ang II + BAY 41-2272 low
(2 mg/kg/day)
Ang II + BAY 41-2272 high
(10 mg/kg/day)
In a rat model of hypertension, BAY 41-2272 ameliorated
angiotensin II-induced cardiovascular remodeling, and the effects
on the extracellular matrix may have been exerted partially via
cGMP, independently of blood pressure
Masuyama et al.,
2009 [34]
BAY 41-2272 Surgery control
Pressure overloaded
Pressure overloaded + BAY
41-2272
In a rat model of hypertension, BAY 41-2272 had no effects on
blood pressure, but decreased aortic constriction-induced
collagen accumulation in the left ventricle, inhibiting the number of
myofibroblasts and gene expressions of TGFb1 and type
1 collagen
Jones et al.,
2009 [31]
BAY 41–2272 BAY 41-2272
BAY 58-2667
Age-matched normotensive
In aged spontaneously hypertensive rats, BAY 41-2272 rapidly
reversed existing pathological cardiac changes, for example by
decreasing fibrosis levels to those of age-matched normotensive
rats
Stasch et al., 2001,
2002 [39,40]
BAY 41-8543 and
BAY 41–2272
Untreated control
BAY 41-2272
Vehicle control
BAY 41-8543
Oral BAY 41-2272 and BAY 41-8543 produced dose-dependent
vasodilation without causing tolerance and significantly improved
survival in rat models of hypertension
Wang-Rosenke
et al., 2011 [45]
BAY 41-8543 Unilateral ureteral obstruction
with obstruction relief
Unilateral ureteral obstruction
with obstruction relief + BAY
41-8543
Administration of BAY 41-8543 to untreated obstructed rats
showing mildly increased systolic blood pressure, marked tubular
atrophy and apoptosis, tubulointerstitial macrophage infiltration,
and fibrosis significantly increased plasma cGMP. This was
paralleled by significant decreases in systolic blood pressure, renal
tubular diameter, apoptosis, and renal macrophage infiltration.
sGC stimulation decreased tubulointerstitial fibrosis, as shown by
tubulointerstitial volume, matrix protein accumulation, a-smooth
muscle actin expression, collagen IV deposition, and TGFb1 mRNA
expression
Current Opinion in Pharmacology 2015, 21:95–104 www.sciencedirect.com
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Table 1 (Continued )
Citation Compound Treatment groups Key findings
Wang-Rosenke
et al., 2012 [43]
BAY 41-8543 Sham surgery control
Unilateral ureteral obstruction
with obstruction relief
Unilateral ureteral obstruction
with obstruction relief + BAY
41-8543
Administration of BAY 41-8543 to rats with unilateral ureteral
obstruction increased cGMP production and led to significant
amelioration of renal matrix protein expansion, macrophage
infiltration, tubular apoptosis, and atrophy
Costell et al.,
2012 [29]
BAY 60-4552 Normal diet
HSFD
HSFD + GSK2181236A low
(0.1 mg/kg/day)
HSFD + GSK2181236A high
(1.0 mg/kg/day)
HSFD + BAY 60-4552 low
(0.3 mg/kg/day)
HSFD + BAY 60-4552 high
(3.0 mg/kg/day)
In spontaneously hypertensive stroke-prone rats, a low dose of
BAY 60-4552 decreased urine output and improved survival. A high
dose also reduced urine output, and in addition reduced
microalbuminuria and attenuated the increase in mean arterial
pressure
Sharkovska et al.,
2010 [38]
Riociguat High renin study
L-NAME only
L-NAME + riociguat low
(3 mg/kg/day)
L-NAME + riociguat high
(10 mg/kg/day)
Low renin study
Sham surgery control
5/6 nephrectomy
5/6 nephrectomy + riociguat
In two independent rat models of hypertension, riociguat reduced
mortality and normalized blood pressure. Renal target organ
damage was reduced in one model, as demonstrated by
reductions in plasma creatinine and urea and less fibrosis. In the 5/
6 nephrectomy model, creatinine clearance was improved and
interstitial fibrosis reduced
Geschka et al.,
2011 [9]
Riociguat Vehicle control
Riociguat low (3 mg/kg/day)
Riociguat high (10 mg/kg/day)
Riociguat-treated salt-sensitive rats fed a high-salt diet had
improved survival and attenuated systemic hypertension and
systolic dysfunction. Fibrotic tissue remodeling and degeneration
were also enhanced in the heart and kidneys
Ott et al., 2012 [35] Riociguat Vehicle control
Telmisartan
Riociguat
Telmisartan + riociguat
Significant reductions in blood pressure and albuminuria were
induced with combined riociguat and telmisartan treatment in
diabetic eNOS knockout mice as compared with diabetic controls
JP Stasch et al.,
unpublished
Vericiguat Vehicle control
Vericiguat
Vericiguat reduced mortality, improved systemic hypertension and
tubulopathy, glomerulopathy, and vasculopathy in salt-sensitive
rats fed a high-salt diet. In a low-NO/high-renin rat model of
hypertension, vericiguat reduced right and left heart hypertrophy
and mortality, and showed a positive effect on grading of kidney
changes, and the incidence and severity of myocardial lesions
Ang, angiotensin; cGMP, cyclic guanosine monophosphate; eNOS, endothelial nitric oxide synthase; HSFD, high-salt/high-fat diet; L-NAME, L-NG-
nitroarginine methyl ester; mRNA, messenger ribonucleic acid; NO, nitric oxide; PAI-1, plasminogen activator inhibitor-1; PBS, phosphate buffered
saline; PDE, phosphodiesterase; sGC, soluble guanylate cyclase; TGFb, transforming growth factor beta.stroke-prone, spontaneously hypertensive rats, BAY 60-
4552 improved survival (Figure 2c), attenuated the de-
velopment of hypertrophy, reduced urine output and
microalbuminuria, and attenuated increases in blood
pressure compared with untreated controls [29].
Riociguat
Riociguat (BAY 63-2521) is the most advanced of the sGC
stimulators. It has been approved for use in pulmonary
arterial hypertension and chronic thromboembolic pul-
monary hypertension [46,47], and is in clinical develop-
ment for a number of other indications [48]. Riociguat is a
heme-dependent sGC stimulator closely related to BAY
41-2272 and BAY 41-8543 [10]. In two independent rat
models of hypertension, riociguat had a potent protective
effect against cardiac and renal damage. In the firstwww.sciencedirect.com model (low-NO/high-renin), riociguat induced a marked
dose-dependent decrease in renal interstitial fibrosis and
normalized blood pressure versus control rats [38]. In a
subtotal nephrectomy rat model, riociguat-treated rats
exhibited significantly lower blood pressure compared
with untreated sham-operated animals, and had a signifi-
cantly higher creatinine clearance compared with untreat-
ed rats [38]. Furthermore, in a model of chronic volume
and pressure overload using salt-sensitive Dahl rats fed a
high-salt diet, riociguat significantly reduced glomerulo-
sclerosis and interstitial and perivascular fibrosis, and
significantly decreased mortality, compared with vehi-
cle-treated rats [9]. In addition, riociguat in combination
with telmisartan has been studied in a diabetic eNOS
knockout mouse model, where animals were previously
treated with an angiotensin II receptor blocker. SignificantCurrent Opinion in Pharmacology 2015, 21:95–104
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(a) Example of effects of soluble guanylate cyclase stimulators on systolic blood pressure (BAY 41-2272) (reproduced from [36]). Effects of the
pharmacologic soluble guanylate cyclase stimulator BAY 41-2272 (10 mg/kg/day) in rats with induced anti-thy1 glomerulonephritis (GN). Blood pressure
was measured in conscious animals using a tail cuff method. *P < 0.01 versus GN. (b) Example of effect on fibrosis (BAY 41-2272) (reproduced from
[44]). Area of fibrosis in rats treated with control, treated chronically with chronic N-nitro-L-arginine methyl ester (L-NAME; 20 mg/rat/day for eight weeks)
alone or in association with BAY 41-2272 (10 mg/kg/day) or treated with BAY 41-2272 alone. Results are expressed as mean  SEM.
*P < 0.01 compared with control group, **P < 0.01 compared with L-NAME group. (c) Example of effect on survival (BAY 60-4552) (reproduced from
[29]). Survival following chronic administration of BAY 60-4552 (0.3 or 3.0 mg/kg/day) or GSK2181236A (0.1 or 1.0 mg/kg/day) in spontaneously
hypertensive prone Sprague rats on a high-salt/high-fat diet (HFSD) versus rats on HFSD alone or no diet (ND). Results are expressed as mean  SEM.
*P < 0.001 versus HFSD. **P < 0.01 versus HFSD. ***P < 0.05 versus HFSD. (d) Example of effect on albumin reduction (riociguat) (reproduced from
[35]). Percentage reduction in urinary albumin excretion per day in diabetic, endothelial nitric oxide synthase knockout mice treated with riociguat (3 mg/
kg/day), telmisartan (1 mg/kg/day), and both (3 mg/kg/day and 1 mg/kg/day) compared with diabetic controls. Results are expressed as mean  SEM.
*P < 0.05 compared with diabetic vehicle. (e) Example of effect on creatinine clearance upon 5/6 nephrectomy (cinaciguat) (reproduced from [32]).
Change in creatinine clearance in male Wistar rats who were allocated to three groups: 5/6 nephrectomy, 5/6 nephrectomy treated with cinaciguat
(50 mg/day), and sham operation. Results are expressed as mean  SD. *P < 0.001 versus sham operation. **P < 0.05 versus 5/6 nephrectomized rats.
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diabetic nephropathy, were observed compared with dia-
betic controls (Figure 2d) [35].
The combination of promising preclinical data and fur-
ther positive clinical trials have led to the approval of
riociguat (Adempas1), making it the first of the sGCTable 2
Summary of studies investigating sGC activators in experimental
53,54,55,56]
Citation Compound Treatment groups 
Kalk et al.,
2006 [32]
Cinaciguat Sham surgery control
5/6 nephrectomy
5/6 nephrectomy + cinaciguat
Fang et al.,
2012 [53]
Cinaciguat Untreated control
Cinaciguat
Chen et al.,
2014 [55]
Cinaciguat Vehicle
ACE-i + CCB
ACE-i + cinaciguat
Hoffmann et al.,
2014 [27]
Cinaciguat High-salt diet only
High-salt diet + cinaciguat
Dautzenberg et al.,
2014 [22]
Cinaciguat Vehicle control
Cinaciguat
Benz et al.,
2007 [54]
Ataciguat Sham surgery control
Subtotal nephrectomy
Subtotal nephrectomy
+ ataciguat
Subtotal nephrectomy + ACE-
Schafer et al.,
2010 [37]
Ataciguat Sham surgery control
Left coronary arterial
ligation + placebo
Left coronary arterial
ligation + ataciguat
Harrison et al.,
2014 [56]
BI 703704 Vehicle
BI 703704 at doses
of 0.3, 1, 3,
and 10 mg/kg/day
Costell et al.,
2012 [29]
GSK2181236A Vehicle
GSK2181236A 0.1 mg/kg
GSK2181236A 1.0 mg/kg
ACE-i, angiotensin-converting-enzyme inhibitor; CCB, calcium channel blo
pressure; mRNA, messenger ribonucleic acid; NO, nitric oxide; sGC, soluble
ZSF1 obese.
www.sciencedirect.com stimulators to be approved for clinical use in any indica-
tion [48].
Vericiguat
Vericiguat (BAY 1021189), a more recent sGC stimulator,
improved survival, systemic hypertension and tubulopa-
thy, glomerulopathy, and vasculopathy in salt-sensitive models of kidney and cardiovascular disease [22,27,29,32,37,
Key findings
Cinaciguat treatment of 5/6 nephrectomized rats reduced blood
pressure, left ventricular weight, cardiac arterial wall thickness, and
cardiac myocyte diameter compared with control rats. Creatinine
clearance, glomerulosclerosis, and fibrosis were also improved
with cinaciguat treatment
In type-1 diabetic rats treated with cinaciguat the urinary
protein:creatinine ratio was attenuated, and there was reduced
glomerular sclerosis and tubular damage. Cinaciguat treatment
also significantly decreased the elevated TGFb mRNA levels seen
in the diabetic rats and the desmin expression of podocytes
In a rat model of type-2 diabetic nephropathy (ZSF1),
administration of cinaciguat in combination with an ACE-i resulted
in a significant reduction in the incidence of glomerulosclerosis and
tubulointerstitial lesions compared with vehicle, with benefits
sustained beyond treatment discontinuation. Such an effect was
not observed in the ACE-i + CCB group, demonstrating its
dissociation from MAP lowering.
Long-term cinaciguat treatment of salt-sensitive rats on a high-salt
diet resulted in significantly improved survival and reductions in
blood pressure and heart rate compared with control animals. Urea
and protein levels in urine and uric acid levels in plasma were also
reduced with cinaciguat treatment. Furthermore, biomarkers of
inflammation and fibrosis in the kidney and left ventricle were also
lower with treatment. Likewise, cardiac function and fibrotic
remodeling were improved
Under NO-deficient conditions, cinaciguat treatment of intact
anaesthetized rats at least partly stabilized the resultant
hypertension and renal vasoconstriction, and re-established the
modulation of renal blood flow autoregulation
i
In subtotal nephrectomized rats, ataciguat treatment ameliorated
the increases in urinary albumin and glomerular cell number
induced by the surgery and observed in the untreated rats. In
addition, relative kidney and left ventricular weight were reduced
In a model of chronic heart failure, ataciguat-treated rats
demonstrated improved vasomotor function and reduced platelet
activation
In a rat model of type-2 diabetic nephropathy (ZSF1) BI
703704 treatment resulted in significant reductions in proteinuria
and the incidence of glomerulosclerosis and interstitial lesions
compared with vehicle. Beneficial effects were observed at doses
that did not significantly alter MAP and HR
Models used were: Sprague Dawley rats during coronary artery
ischemia/reperfusion; and, spontaneously hypertensive stroke
prone rats on HSFD
Low dose GSK2181236A attenuated the development of cardiac
hypertrophy, while the high dose also improved survival.
Vasodilatory responses to GSK2181236A were unaltered by HSFD
cker; HR, heart rate; HSFD, high-salt/high-fat diet; MAP, mean arterial
 guanylate cyclase; TGFb, transforming growth factor beta; ZSF1, male
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102 Cardiovascular and renalDahl rats fed a high-salt diet (JP Stasch et al., unpub-
lished). In a low-NO/high-renin rat model of hyperten-
sion, vericiguat reduced right and left ventricle
hypertrophy and mortality, and showed a positive effect
on grading of kidney changes, and the incidence and
severity of myocardial lesions [49–53,54]. The potential-
ly beneficial effects of vericiguat on cardiac function are
supported by the findings from recently completed phase
I studies, which found that this agent leads to improve-
ment in important cardiologic parameters, including:
cardiac output/index, systemic vascular resistance, and
stroke volume [49]. Clinical phase IIb trials are now
underway in patients with heart failure who have reduced
or preserved ejection fraction (SOCRATES,
NCT01951625, and NCT01951638) [52].
sGC activators
Effect of sGC activators in experimental kidney and
cardiovascular disease
The effects of the sGC activators cinaciguat, ataciguat, BI
703704, and GSK2181236A have been investigated in
experimental models of kidney and cardiovascular dis-
ease (Table 2).
Cinaciguat (BAY 58-2667)
Several studies have demonstrated that cinaciguat has a
protective renal effect. In rats with subtotal nephrectomy,
chronic cinaciguat treatment lowered blood pressure,
preserved renal function, improved plasma levels of na-
triuretic peptides, reduced left ventricular hypertrophy
and cardiac arterial wall thickness, and slowed renal
disease progression compared with untreated controls
(Figure 2e) [32]. Cinaciguat was further shown to inhibit
podocyte damage, tubular damage, and glomerulosclero-
sis in a type-1 diabetic rat model of nephropathy [53]. In a
rat model of type-2 diabetic nephropathy, administration
of cinaciguat, together with the angiotensin-converting-
enzyme inhibitor enalapril, resulted in significant and
sustained reductions in glomerulosclerosis and tubuloin-
terstitial lesions, compared with controls [55]. Under
NO-deficient conditions, cinaciguat treatment of intact
anesthetized rats at least partly stabilized the resultant
hypertension and renal vasoconstriction, and re-estab-
lished the modulation of renal blood flow autoregulation
[22]. In a salt-sensitive rat hypertension model, long-term
cinaciguat was associated with markedly improved
survival, a lower increase in blood pressure, improve-
ments in cardiac and renal function, and anti-fibrotic
and anti-inflammatory effects compared with untreated
controls [27].
Ataciguat (HMR1766)
A new structural class of sGC activators includes the novel
anthranilic acid derivative, ataciguat [37]. In a rat model
of congestive heart failure, chronic treatment with ataci-
guat improved vascular function and sensitivity to
NO, and reduced platelet activation [37]. In a rat modelCurrent Opinion in Pharmacology 2015, 21:95–104 of non-inflammatory renal failure, ataciguat showed ben-
eficial blood pressure-independent renoprotective effects
on kidney structure and urinary albumin excretion com-
pared with untreated controls [54].
BI 703704
Recently presented but limited data showed BI 703704 to
have a significant renal protective effect in a rat model of
diabetic nephropathy when compared with untreated
controls, with reductions in proteinuria and the incidence
of glomerulosclerosis observed at doses that did not
significantly alter blood pressure or heart rate [56].
GSK2181236A
Limited published data suggest that GSK2181236A may
provide partial benefit against hypertension-induced end-
organ damage in rat models [29].
Taken together, these results suggest that sGC activators
also have the potential to provide pressure-independent
renal and cardiac protection.
Discussion and conclusion
In in vivo experimental models of kidney and cardiovas-
cular disease, the sGC stimulators BAY 41-2272, BAY 41-
8543, BAY 60-4552, riociguat, and vericiguat have dem-
onstrated protection against renal target organ damage in
experimental CKD models (Table 1). It is of note that
this class of new drugs worked in the CKD models nearly
independent of the underlying cause of CKD. We tested
models of reduction of nephron numbers, malignant
hypertension, immunological induced glomerulonephri-
tis, and finally diabetic kidney disease were tested. Stim-
ulation of sGC and subsequent cGMP production
represents an important common pathway in the mainte-
nance of renal function independent of the initial under-
lying cause of CKD, and therapeutic use of these sGC
stimulators has been shown to produce a broad range of
antifibrotic, antiproliferative, and antiproteinuric effects.
It is of note that this new class of drugs can also improve
blood pressure control at higher doses. This is of major
clinical impact, since most patients with CKD suffer from
hypertension which is an independent progression factor
of CKD.
The results indicate that sGC stimulators may be capable
of restoring physiological signaling in disorders where
cGMP signaling has been disrupted. The sGC system
has an important physiological role in both vascular and
non-vascular tissues so the beneficial effects may extend
to restoring the endothelium-mediated regulation of
myocardial and renal function [51]. In addition, in in
vivo models mirroring the pathophysiology of different
subtypes of CKD and cardio-renal syndrome, the sGC
activators cinaciguat, ataciguat, BI 703704, and
GSK2181236A were capable of protecting and improving
physiological renal function (Table 2).www.sciencedirect.com
Renal effects of soluble guanylate cyclase stimulators and activators Stasch, Schlossmann and Hocher 103In conclusion, preclinical data suggest that both sGC
stimulators and sGC activators may offer therapeutic
benefits for patients with CKD, on top of guideline-based
renin–angiotensin system blockade. These novel drugs
have the potential to address an unmet medical need in
CKD, by providing an alternative for those patients in
whom currently available guideline-recommended treat-
ments alone are ineffective, and who are consequently at
risk for rapid progression to ESRD. Clinical trials are
required to confirm and extend these preclinical findings
to humans.
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